IRVINE, Calif.--(BUSINESS WIRE)--Immunis, Inc., a leading private biotech at the forefront of innovative immunomodulatory secretome therapeutics for age-related diseases, is proud to announce that its Chairman, Hans Keirstead, Ph.D., has once again been named one of Orange County Business Journal’s OC 500 for 2023. Selection for this honor is based on a comprehensive merit assessment, recognizing top executives, government leaders, philanthropists, and other prominent civic figures who have made significant contributions to the Orange County business community.
Dr. Keirstead's recognition stems from his pivotal role in advancing biotechnological innovation. As Chairman of Immunis, he has been instrumental in guiding the development of the company's groundbreaking investigational secretome product (IMMUNA), which is being researched as an immunomodulator for several age-related diseases. Immunis is actively enrolling patients in its FDA-approved Phase 1/2a clinical trial to determine the safety and tolerability of IMMUNA in people with age-related muscle atrophy. There are currently no FDA-approved secretome drugs on the market and there are no treatments for sarcopenia, making IMMUNA a potentially groundbreaking therapy.
“I am deeply honored to receive this recognition and to be a part of Orange County's dynamic business and research ecosystem. This acknowledgment fuels our commitment to innovating and transforming healthcare,” says Dr. Keirstead.
The Immunis team extends heartfelt congratulations to Dr. Keirstead on this achievement. His visionary leadership and contributions continue to drive the company forward.
Congratulations, Dr. Keirstead!
About Immunis Inc.
Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The investigational product line leverages Immunis’ leading-edge capabilities in secretome technology to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ Phase 1/2a clinical trial please visit: https://immunisbiomedical.com/clinical-trials/
Cautionary Note Regarding Forward-Looking Statements
This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.
